Serum Creatine Kinase and Magnesium as Prognostic Indicators in Acute Organophosphorus Poisoning by Subramanian, R
  
DISSERTATION 
on 
SERUM CREATINE KINASE AND MAGNESIUM AS 
PROGNOSTIC INDICATORS IN ACUTE 
ORGANOPHOSPHORUS POISONING 
submitted in partial fulfillment of 
requirements for 
MD DEGREE EXAMINATION 
BRANCH-I GENERAL MEDICINE 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
INSTITUTE OF INTERNAL MEDICINE 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600003 
APRIL 2013  
  
CERTIFICATE 
This is to certify that the dissertation titled “SERUM CREATINE 
KINASE AND MAGNESIUM AS PROGNOSTIC INDICATORS IN 
ACUTE ORGANOPHOSPHORUS POISONING” is a bona fide work 
done by Dr. R. SUBRAMANIAN, Post Graduate student, Institute of 
Internal Medicine, Madras Medical College, Chennai – 600003, in partial 
fulfillment of the university rules and regulations for the award of MD 
DEGREE in GENERAL MEDICINE BRANCH-I, under our guidance 
and supervision, during the academic period from April 2010 to April 
2013. 
 
 
 
Prof. N. RAGHU, MD, 
Professor and Director, 
Institute of Internal Medicine, 
MMC and RGGGH, 
Chennai – 600003. 
 
Prof. V. KANAGASABAI, MD, 
Dean, 
MMC and RGGGH, 
Chennai – 600003. 
  
  
DECLARATION 
I solemnly declare that the dissertation titled “SERUM CREATINE 
KINASE AND MAGNESIUM AS PROGNOSTIC INDICATORS IN 
ACUTE ORGANOPHOSPHORUS POISONING” was done by me at 
Madras Medical College, Chennai – 600003, during the period June 2012 
to November 2012 under the guidance and supervision of Prof. N. 
RAGHU, MD, to be submitted to The Tamil Nadu Dr. M.G.R. Medical 
University towards the partial fulfillment of requirements for the award of 
MD DEGREE in GENERAL MEDICINE BRANCH-I. 
 
Place : Chennai 
Date :24/12/2012 
Dr. R. SUBRAMANIAN, 
MD GENERAL MEDICINE, 
Post Graduate Student, 
Institute of Internal Medicine, 
Madras Medical College, 
Chennai – 600003. 
  
  
ACKNOWLEDGEMENT 
I thank Prof. V. KANAGASABAI, MD, Dean, Madras Medical 
College, for having permitted me to conduct the study and use the 
hospital resources in the study. 
I express my heartfelt gratitude to Prof. N. RAGHU, MD, Director, 
Institute of Internal Medicine, for his inspiration, advice and guidance in 
making this work complete. 
I am extremely thankful to Dr. M. ANUSUYA, MD, Assistant 
Professor, Institute of Internal Medicine and Dr. D.K. SIVAKUMAR, 
MD, Assistant Professor, Institute of Internal Medicine, for guiding me 
academically and professionally during the period of study. 
I also thank all the postgraduate students and paramedical staff for 
their cooperation which enormously helped me in the study. I am also 
indebted to thank all the patients and their caring relatives. Without their 
humble cooperation, this study would not have been possible. 
  
  
ABBREVIATIONS 
CK creatine kinase 
Mg magnesium 
OPC organophosphate compounds 
Ach acetyl choline 
AchE acetylcholinesterase 
Ch choline 
ODIDP organophosphate induced delayed polyneuropathy 
COPIND chronic organophosphate induced neuropsychiatric disorder 
POP Paradeniya organophosphorus poisoning  
SGOT serum glutamate oxaloacetate transaminase 
LDH lactate dehydrogenase 
mg milligram 
IU international units 
dl deciliter 
gm gram 
P2AM pralidoxime 
  
  
TABLE OF CONTENTS 
1.  INTRODUCTION 1 
2.  OBJECTIVES 3 
3.  REVIEW OF LITERATURE 4 
4.  MATERIALS AND METHODS 33 
5.  RESULTS 36 
6.  DISCUSSION 72 
7.  CONCLUSION 76 
8.  RECOMMENDATIONS AND AREAS OF 
FUTURE RESEARCH 
77 
9.  SUMMARY 78 
10. BIBLIOGRAPHY 79 
11. ANNEXURES 
 PROFORMA 83 
 INFORMATION SHEET 85 
 CONSENT FORM 86 
 ETHICAL COMMITTEE APPROVAL FORM 87 
 TURNITIN DIGITAL RECEIPT 88 
 ANTI-PLAGIARISM REPORT 89 
 MASTER CHART 90 
 
1 
 
INTRODUCTION 
 Agriculture constitutes the major component of Indian economy.  
Pesticides are wonderful human inventions used for the control of pests, 
weeds or plant diseases to improve the cultivation of agricultural 
products.  It also had been used as chemical warfare weapons. 
 In India, agriculture is still labour-intensive.  So, man is exposed to 
such chemicals at all stages of pesticide formulation, manufacturing and 
spraying in his farm.  Pesticides has got both acute and chronic health 
hazards upon exposure either by occupational or by self- harm(1).   
 Poisoning constitutes about 60% of self-harm(1) in rural Asia.  
Organophosphate compounds account for 80% of pesticide poisoning.  
Ravi et al described the incidence of organophosphorus poisoning  as 
around 1.26 lakhs during the year 2007 in India.  In our poison centre, 
Rajiv Gandhi Government General Hospital, Chennai, 330 and 244 cases 
of acute organophosphorus poisoning admitted respectively in 2010 and 
2011 with a mortality rate of 19%  mostly due to respiratory paralysis and 
mechanical ventilation related complications.   
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Even with this background, the medical management of acute 
organophosphorus poisoning is deficient in evidence based management 
protocols and research tool.  This calls for our urgent comprehensive 
analysis of acute organophosphorus poisoning which may be helpful in 
renovating the protocol in its management to reduce mortality.   
  
3 
 
OBJECTIVES 
 
1. To assess and categorize the severity of organophosphorus 
poisoning cases clinically, on admission by Peradeniya 
Organophosphorus Poisoning scale. 
2. To estimate the serum levels of creatine kinase and magnesium 
on admission in acute organophosphorus poisoning. 
3. To correlate the serum levels of creatine kinase and magnesium 
with the clinical severity scoring. 
4. To correlate the serum levels of creatine kinase and magnesium 
with the atropine requirement during the course in hospital. 
5. To correlate the serum levels of creatine kinase and magnesium 
with one or more of complications like respiratory paralysis, 
intermediate syndrome and the need for mechanical ventilation, 
acute renal failure, seizures, arrhythmias and coma.   
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REVIEW OF LITERATURE 
Historical Background 
 Organophosphorus compounds are a diverse group of chemicals 
used as pesticides.  They have been first synthesized by Lassaigne during 
early 1800s on observing the reaction of alcohol with phosphoric acid.  In 
1854, Clermont(2) prepared Tetro Ethyl Pyrophosphate (TEPP).  Lange 
succeeded in the synthesis of dimethyl diethyl phosphor fluoridates in 
1932.  Lange in Berlin investigated the use of these chemicals as 
pesticides, but German military(3) used it as chemical warfare agents (i.e. 
tabun, sarin, soman).  In 1941, during World War II, the 
organophosphates were reintroduced as insecticides as originally 
intended.  Jamaican Jinger Palsy incident in 1930, due to suicidal and 
accidental exposure to organophosphate compounds led to probe into its 
mechanism of action.  In 1944, Schrader, synthesized parathion and was 
widely used as insecticides.  In 1955, Davies introduced oximes and its 
usefulness in organophosphorus poisoning.  Mass poisoning happened in 
2005, following ethion contaminated food in India.   
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 Organophosphorus compounds are basically the esters of 
phosphoric acid in which a terminal oxygen is connected to phosphorus 
by a double bond, whereas two lipophilic groups and a leaving group is 
connected to phosphorus by a single bond.   
 
 
 
 
 
 
R – denotes either ethyl or methyl group 
X – denotes leaving group 
 Leaving group is the principal metabolite for species identification. 
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PHARMACOKINETICS 
 Organophosphates can be absorbed percutaneously and also when 
ingested, inhaled or injected.  The kinetics depend upon many factors 
such as: 
1. Route of administration 
2. Distance from target organs 
3. Local vs systemic metabolism and activation 
4. Route of elimination 
5. Endogenous hydrolysis by non-specific esterases.    
The chemicals are equally distributed in all tissues but 
predominantly in liver and kidneys.  Plasma half life ranges from few 
minutes to few hours depending upon the type of compounds and route of 
exposure.  Metabolism occurs either by oxidation, hydrolysis by esterases 
or by transfer of portion of molecule to glutathione.  80 – 90% of 
compound is eliminated within 48 hours of exposure by urinary and fecal 
excretion.  Most of agents show symptoms and signs within six to ten 
hours of exposure with the exception of fat soluble compounds where it 
may take several days to weeks to manifest because the substance may be 
leached out of the fat.   
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CLASSIFICATION OF ORGANOPHOSPHORUS 
COMPOUNDS(4) 
A.HIGHLY TOXIC 
Monochrotophos 
Phosphamindon 
Ethyl Parathion 
Chlorthiophos 
Dichlorovas 
Methyl Parathion 
B.MODERATELY TOXIC 
Malathion 
Chlorpyrifos 
Temephos 
Diazinon 
Fenthion 
C.LEAST TOXIC 
Triazophos 
Parathion 
Quinalphos 
Dimethoate 
Prophenophos  
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Figure 1: Organophosphorus compounds commonly encountered in our 
poison center 
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MECHANISM OF ACTION 
 Acetylcholine (Ach) is the neurotransmitter in central and 
peripheral nervous system at all postganglionic parasymphathetic nerve 
endings, at synapses of both sympathetic and parasympathetic ganglia 
and also at skeletal muscle myoneural junction.  Acetyl cholinesterase 
(AchE) is an enzyme localized in central nervous system in various 
organs and glands which hydrolyses acetylcholine into acetic acid and 
choline (Ch). 
 AchE is present in two forms. 
1. True acetyl cholinesterase – found in tissues and erythrocytes 
2. Pseudocholinesterase – found in serum and liver.   
Organophosphates are the acid transferring inhibitors of 
cholinesterase by phosphorylation of the enzyme.  The reactivation of 
enzyme may occur spontaneously or may be enhanced by oximes. 
  Acetylcholine binds with acetylcholinesterase enzyme and 
forms acetylcholine-enzyme complex. Subsequently the enzyme gets 
acetylated. The acetylated enzyme undergoes hydrolysis and forms acetic 
acid and choline releasing the free enzyme. This physiological reaction is 
a rapid one. 
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In the presence of organophosphorus compounds, the 
acetylcholine-enzyme complex becomes phosphorylated instead of 
getting acetylated. Once the enzyme becomes phosphorylated, its 
conversion to free enzyme is a very slow process. Non-availability of free 
enzyme leads to excess acetylcholine in the synapse and neuromuscular 
junction leading onto the toxic clinical consequences. Oximes accelerate 
the conversion of phosphorylated enzyme to free enzyme. 
 
  
Ach + AchE 
Ach-Enzyme 
complex 
Acetylated 
enzyme 
Acetic acid + 
Choline + Free 
enzyme 
Phosphorylated 
enzyme 
OPC 
Rapid 
Very slow Rapid 
with 
oximes 
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CLINICAL FEATURES 
Symptoms and signs of organophosphorus poisoning: 
Muscarinic manifestations 
GASTRO-INTESTINAL 
 Nausea / vomiting 
 Increased salivation 
 Diarrhoea 
CARDIO-VASCULAR 
 Hypotension 
 Bradycardia 
 Arrythmias 
RESPIRATORY 
 Rhinorrhea 
 Bronchorrhea 
 Bronchospasm 
GENITO URINARY 
 Urinary incontinence 
EYES 
 Diplopia 
 Lacrimation 
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 Miosis 
GLANDS 
 Salivation 
 Sweating 
 
Nicotinic manifestations 
MUSCULO-SKELETAL(5) 
 Weakness 
 Fasciculation 
 Cramps 
 Paralysis 
CARDIO-VASCULAR 
 Hypertension 
 Tachycardia 
 Arrythmias 
 
Central manifestations 
 Anxiety 
 Ataxia 
 Convulsions 
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 Insomnia 
 Tremors 
 Dysarthria 
 Coma 
 Absent reflexes 
 Respiratory depression 
 
The manifestations of toxic features of organophosphorus 
compounds depend on the agent, quantity, route of entry, rate and amount 
of systemic absorption and are usually seen within 30 minutes to 3 hours. 
Gastrointestinal manifestations: 
 Symptoms of vomiting, diarrhoea and abdominal cramps are first 
to occur after oral ingestion. 
Respiratory manifestations: 
 The integrity of airway will be compromised by excessive 
secretions.  Paralysis of both respiratory and oropharyngeal muscles 
occur due to nicotinic effects leading on to airway obstruction and 
aspiration of gastric contents. Central nervous system depression leads to 
respiratory arrest. 
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Cardiac manifestations(6): 
 They are often the cause for serious complications and fatality.  
Mechanisms may be due to direct toxicity on the myocardium or due to 
other contributory factors like hemodynamic alteration, acidosis, hypoxia, 
electrolyte abnormalities and high dose atropine therapy.   
Neurological manifestations: 
 It has been the primary focus of interest which may necessitate 
prolonged mechanical ventilation due to neuromuscular weakness. 
 
Type I paralysis or acute cholinergic crisis: 
 It is seen in initial phase of exposure characterized by muscle 
fasciculation, weakness, cramps, may require ventilator support. This 
phase usually passes off within  48 – 72 hours.  Muscle fiber necrosis 
have been described in this phase and leads to increased serum levels of 
muscle enzymes(7). 
Type II paralysis or Intermediate syndrome(8): 
 It usually develops 12 – 96 hours of exposure.  The proposed 
mechanisms for development of intermediate syndrome are: 
a. Different susceptibility of various cholinergic receptors 
b. Muscle necrosis 
c. Prolonged AchE inhibition 
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d. Inadequate oxime therapy 
e. Oxidative stress related myopathy 
This phase is characterized by weakness of neck flexors, 
respiratory muscles, proximal limb muscles and motor cranial nerves like 
III, IV and VI with sparing of distal muscle groups.  This phase persists 
for 4 – 18 days and may require mechanical ventilation. 
Type III paralysis or organophosphate induced delayed 
polyneuropathy (OPIDP)(9) 
 This type of distal motor axonopathy follows after a period of 7 – 
21 days of exposure which is usually manifested by weakness of small 
muscles of hands and foot drop with sparing of cranial nerves and 
autonomic nervous system.  Deep tendon reflexes will be absent.  Severe 
manifestations will be left with persistent deficits. 
Chronic Organophosphate induced neuropsychiatric disorder 
(COPIND)(10) 
 These are the long term effects following the acute exposure to 
high dose of organophosphorus compounds.  The manifestations are 
anxiety, depression, memory disturbances, schizophrenia, dystonic 
reactions,cog-wheel rigidity.  The cause could be attributed to the 
sequelae of cardiac arrhythmias, convulsions, respiratory failure and 
anoxia. 
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Immunological alterations: 
 Severe cholinergic stimulation may suppress the immune system 
either directly by acetylcholine or indirectly by the metabolic products of 
organophosphorus compounds.  There may be a decrease in neutrophil 
chemotaxis.  It will lead onto autoimmune reactions and suppresses the 
antibody response to vaccines.  The individuals are more prone for 
frequent viral infections in long term. 
Endocrine manifestations: 
 There may be increased release of hormones such as 
Adrenocorticotrophic hormone (ACTH), Prolactin and Vasopressin due 
to effect on nicotinic receptors in brain.  Non-ketotic hyperglycemia, 
glycosuria and reduced thyroxin production are other consequences.   
CLINICAL SEVERITY SCORING: 
 The following are the grading of clinical severity useful in 
organophosphorus poisoning. 
1. Poisoning Severity Scale (PSS) 
2. Modified Dreisbach Clinical Criteria 
3. Peradeniya Organophosphorus Poisoning scale    
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The Peradeniya Organophosphorus Poisoning scale(7): 
Parameters Criteria Score 
Pupil size 
>2mm 0 
<2mm 1 
Pin point 2 
Respiratory rate 
<20/min 0 
>20/min 1 
>20/min with central cyanosis 2 
Heart rate 
>60/min 0 
41 – 60/min 1 
<40/min 2 
Fasciculation 
None 0 
Present, generalized / continuous 1 
Both generalized and continuous 2 
Level of 
consciousness 
Conscious and rationale 0 
Impaired response to verbal commands 1 
No response to verbal commands 2 
Seizures 
Absent 0 
Present 1 
 
Note : 0 – 3 Mild Poisoning; 4 – 7 moderate poisoning; 8 – 11 severe 
poisoning 
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DIAGNOSTIC MODALITIES 
I. Enzyme Levels: 
i. Cholinesterase: 
The diagnosis of organophosphorus poisoning may be confirmed by 
the reduction of RBC cholinesterase activity(11), expressed as 
percentage, for which results won’t be readily available.  Hence, 
RBC cholinesterase level is a useful marker which correlates better 
with CNS acetylcholine levels than plasma cholinesterase.  It may 
show false positive results due to its depressed levels seen in 
pernicious anemia, hemoglobinopathies and with the use of 
antimalarial drugs. Plasma cholinesterase levels below 5000 IU/L 
can be taken as the corroborative evidence of organophosphorus 
poisoning.  Since it is an acute phase reactant produced in liver, it 
can be increased during pregnancy and infections.  Its level may be 
low in liver dysfunction, low protein conditions, use of drugs like 
succinylcholine, codeine, morphine, etc., 
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ii. Creatine kinase: 
Creatine kinase(12) is the enzyme expressed by various tissues like 
skeletal muscles, heart, brain, retina, hair cells of inner ear and 
smooth muscles.  It catalyses the conversion of creatine to 
phosphocreatine by consuming ATP to form ADP. 
 
 
 
 They exist as two forms. 
1. Mitochondrial CK enzyme 
2. Cytosolic CK → 3 isoenzymes 
CK-MM → Skeletal muscles 
CK-MB  → Heart 
CK-BB  →  Brain 
 Normal levels of creatine kinase in serum is between 60 -400 IU/L.  
In acute organophosphorus poisoning, serum CK level is elevated both in 
acute cholinergic phase and intermediate syndrome due to muscle fiber 
necrosis. 
           ATP ADP 
Creatine Phosphocreatine 
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 Other conditions causing elevated serum CK are chronic alcohol 
abuse, myopathies, chronic liver disease, malignancy, renal failure, 
seizure, myocardial infarction, drugs like statins, steroids, etc.,  
iii. Other enzymes: 
SGOT, LDH, amylase, lipase may be elevated . 
II. Gastric aspirate and blood analysis – for estimation of 
organophosphate compounds.   
III. Renal Function Test: 
 Elevated serum creatinine and BUN 
 Hypokalemia 
 Hyperkalemia 
IV. Complete Blood count – Leukocytosis and hemoconcentration due 
to fluid loss.   
V. Arterial Blood Gas analysis  - Metabolic acidosis, hypoxia, 
hypercapnia 
VI. Chest X Ray – Aspiration pneumonitis, pulmonary edema 
VII. Electrocardiogram – Prolonged Q-T interval, S-T segment 
elevation, prolonged P-R interval, sinus brady/tachycardia, 
ventricular tachycardia, ventricular fibrillation. 
There are three phases of cardiotoxicity described by Ludomirsky et 
al. 
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Phase I  -   A brief period of increased sympathetic tone 
Phase II -   Prolonged period of parasympathetic tone with A-V  
    blockade 
Phase III -   QT prolongation, Torsades  de pointes(TdP), 
ventricular  
    Tachycardia / fibrillation. 
 
VIII. Nerve Conduction Study(13) :  
 Repetitive firing from single stimulus 
 Decremental – incremental response 
 Decremental response 
IX. Serum Magnesium 
Acute Organophosphorus poisoning will produce 
hypomagnesemia(14) due to: 
 Prolonged nasogastric suction 
 Severe diarrhea 
 Underlying illness like starvation, chronic alcoholism, 
diabetes, hyperthyroidism, chronic kidney disease. 
 Normal plasma magnesium concentration is 1.7 – 2.1 mg/dl. 
Magnesium is involved in metabolism of proteins, fats and 
carbohydrates and act as cofactor for the enzyme ATPase. 
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Extracellularly, magnesium ion interferes with the release of 
acetylcholine and blocks neurosynaptic transmission.  Hypokalemia is 
usually associates with hypomagnesemia. 
 
Manifestations of hypomagnesemia 
CARDIAC 
 Arrythmias – 
Atrial/Ventricular 
 Hypertension 
NEUROMUSCULAR 
 Convulsions 
 Muscle cramps 
 Depression 
 Generalised weakness 
 Acute organic brain 
syndrome 
 Since the features of hypomagnesemia may be masked by 
organophosphorus toxic manifestations, its serum level may predict the 
outcome of patients with acute organophosphorus poisoning.  
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Studies relating to serum creatine kinase and magnesium levels to the 
severity of acute organophosphorus poisoning 
1. A study conducted at Kolkata Medical College, India by Kuntal 
Bhattacharyya et al, employing 63 patients of acute 
organophosphorus poisoning found the correlation between initial 
increased serum creatine kinase levels and increased risk for 
complications like respiratory paraysis, arrhythmias, increased 
atropine requirement, acute kidney injury, etc.,   
2. Vanneste Y et al proved the biochemical monitoring of 
rhabdomyonecrosis in organophosphorus poisoning by serum 
acetylcholinesterase and creatine kinase levels.     
3. Dursum Aygun et al studied employing 47 patients with acute 
organophosphorus poisoning and conducted that there was no 
difference in initial serum levels of creatine kinase and aspartate 
aminotransferase in patients with and without intermediate 
syndrome and it may not predict the subsequent development of 
intermediate syndrome.   
4. Shubhakaran et al from Dr.S.N.Medical College, Jodhpur, 
Rajasthan have documented hypomagnesemia in many 
organophosphorus poisoning cases(16). 
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5. Bar-Meir et al proposed hypomagnesemia, hypokalemia or 
hypocalcemia may be the factors causing electrocardiographic 
features of QT prolongation and Torsades de pointes in acute 
organophosphorus poisoning. 
6. Abdolkarim Pajoumand et al from Loghman-Hakim Hospital, 
Tehran, Iran concluded that the administration of MgSO4 
intravenously along with other conventional therapies, will be 
beneficial in reducing the mortality rate(15). 
No study yet conducted correlating the serum levels of magnesium 
with the severity of acute organophosphorus poisoning. 
MANAGEMENT 
General Care 
 Check airway, breathing and circulation. 
 Place the patient in left lateral position with head lower than the 
feet to prevent aspiration. 
 Supplement high flow oxygen and intubate if warranted.   
 Start infusion of Normal Saline to keep systolic blood pressure of 
more than 80 mmHg. 
Skin decontamination 
• Remove all the clothing and gently cleanse the patient with soap 
and water to prevent absorption(17). 
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Eye decontamination 
 Irrigate the eyes with normal saline, if there is ocular exposure. 
 
Gastric lavage 
 Insert nasogastric tube and start lavage within an hour of ingestion 
using Normal Saline or clean tap water 200 – 300 ml each time 
without any dwelling period until vomitus becomes clear.   
 
Activated charcoal 
 Activated charcoal absorbs the poisoning material in gut and 
facilitates excretion by its absorbing and expandable property.  
Multidosing is usually necessary in dose of 1 gm/kg/dose, diluted 
in 150 ml of water with 30 mg of magnesium sulfate every 2 – 4 
hrs for 24 – 48 hours given through Ryle’s tube.  It is 
contraindicated with ileus or with intestinal obstruction.     
The clinical parameters to be monitored in ICU are: 
• Pulse 
• Blood Pressure 
• Respiratory rate 
• Temperature 
• Urine output 
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• Electrocardiogram 
• Fasciculation 
• SPO2 
• Pupillary size 
• Lung signs 
 
Atropine 
 Atropine is the antimuscarinic agent of choice started with the dose 
of 3 – 5 mg rapid intravenous bolus every 5 – 10 minutes till the 
development of signs of atropinisation like: 
 Dry axilla 
 Heart rate >80/min 
 Clear lungs 
 No more pinpoint pupils 
 Systolic BP >80mmHg 
Double the initial dose, if the parameters are not achieved, till 
adequate atropinisation. 
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Then, maintain atropinisation with 10 – 20% of bolus dose given as 
infusion in 100 ml of normal saline with assessment every 15 minutes.  
The dose of atropine should be tailored down hourly for the next 24 
hours.  Watch for atropine toxicity like agitation, confusion, urinary 
retention, ileus, hyperthermia and tachycardia.   
PRALIDOXIME (P2AM): 
 It helps to reactivate the acetylcholinesterase(18).  It has three main 
actions. 
1. A direct reaction converting the organophosphate to a harmless 
compound. 
2. A transient reaction protecting the enzyme from further 
inhibition. 
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3. Reactivation of inhibited alkyl phosphorylated enzyme to free 
the active unit.   
The dose is 30 mg/kg bolus followed by 8 mg/kg/hr for next 48 
hours.  Then, it should be given 1 – 2 gm IV tds for next 5 days, given as 
infusion over a period of one hour in 100 – 200 ml of Normal Saline. 
Rapid infusion may cause neuromuscular blockade, diastolic 
hypertension, convulsions, etc., 
 
Its action is most marked at the nicotinic skeletal neuromuscular 
junction and does not reverse the muscarinic actions.  It should be started 
as early as possible before the permanent binding of organophosphate to 
acetylcholinesterase. 
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Few recent trials have questioned the beneficial effects of P2AM in 
organophosphorus poisoning management(19,20). 
IV Magnesium Sulfate 
 There are few studies quoting the beneficial effects of intravenous 
magnesium sulfate in organophosphorus poisoning.  The probable 
mechanisms are: 
1. Blocks ligand gated calcium channels and reduce the release of 
acetylcholine from presynaptic terminals.  
2. Ventricular membrane stabilization, preventing arrhythmias 
3. Increased hydrolysis of some pesticides. 
Thus, our study is useful in the sense, serum magnesium level may 
correlate with the beneficial effect of intravenous magnesium sulfate. 
Sodium bicarbonate 
 Sodium bicarbonate will increase the blood pH and decrease the 
mortality as per various studies and their effect is independent of 
correction of acidosis. 
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Seizures 
 Controlled with benzodiazepines like diazepam 10 – 20 mg IV or 
Lorazepam 4 mg IV. 
 
Atropine delirium 
 Treated with midazolam 0.1 mg/kg or diazepam 10 – 20 mg IV. 
Mechanical ventilation 
 It may be warranted in respiratory muscle weakness or respiratory 
depression. 
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Therapies under Trial 
Organophosphorus hydrolases(21) 
 Isolated from Pseudomonas species which clears organophosphates 
thus reducing the blood and tissue concentration. 
 N.Methyl / D-Aspartate receptor antagonists 
 Gancyclidine reduces neuronal death, improves 
electroencephalogram and clinical recovery. 
Butrylcholinesterase replacement therapy(21) 
This is favoured by administration of fresh frozen plasma and 
plasmaparesis which increases the level of enzymes in the blood and 
neutralize the organophosphorus compounds. 
 
 
α-2 adrenergic receptor agonists 
 Clonidine inhibits release of acetylcholine from presynaptic 
terminals of neuromuscular junctions. 
Extracorporeal clearance (21) 
 It will be effective for some non-fat soluble organophsphorus 
compounds. 
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PREVENTION AND EDUCATION 
 Improved regulations of availability of pesticides and 
modifications of packaging of pesticides may all help reduced the use of 
organophosphates as poison.  Adequate information to the public, regular 
training of health care providers, better availability of drugs/facilities and 
the establishment of poison information centres will facilitate in reducing 
the morbidity and mortality related to organophosphorus poisoning.   
 Insecticides should be kept out of reach of children to prevent 
accidental poisoning.  Proper protective precautions should be taken 
during agricultural spraying to prevent inhalation and accidental ingestion 
of substance.   
 Pesticide poisoning contributes more than fifty percent of cases in 
our toxicology ICU and carries the mortality of around 19% (case register 
2010 – 11).  Our thesis of serum creatine kinase and magnesium levels in 
organophosphorus poisoning will surely aim in making or correcting the 
protocol for treatment of acute organophosphorus poisoning and also in 
reducing the morbidity and mortality of the patients admitted.   
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MATERIALS AND METHODS 
Setting: 
 This study was conducted in the poison centre,  Institute of Internal 
Medicine, Rajiv Gandhi Government General Hospital , Chennai.It was a 
cross sectional prospective study done during the period from June 2012 
to  November 2012.      
 60 patients, admitted as a case of acute organophosphorus 
poisoning with exposure within 12 hours irrespective of route of 
exposure,  age and sex were selected and subjected for study with the 
consent.   
Exclusion Criteria 
1. Patients with other pesticide poisoning (e.g.organocarbamates)  
have been excluded by history and clinical features. 
2. Patients with mixed poisoning were excluded. 
3. Patients who had taken compounds with alcohol have been 
excluded. 
4. Patients with known medical illness such as chronic liver 
disease, myopathy, malignancy, renal failure, autoimmune 
diseases, seizure disorder, coronary artery disease were 
excluded. 
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5. Patients who were on chronic drug usage with statins, steroids, 
diuretics have been excluded. 
6. Pregnant patients were excluded from the study. 
The eligible patients were assessed clinically on admission by 
Peradeniya Organophosphorus Poisoning scales and categorized 
according to the severity. They were subjected to routine blood 
investigations like blood sugar, blood urea, serum creatinine, liver 
function test, serum acetylcholinesterase, ECG and ABG.  They also have 
been subjected to estimation of serum creatine kinase and magnesium 
levels on admission. 
Bio chemical markers and the methods employed 
1. Cholinesterase  : Kinetic Calorimetric method 
2. Creatine kinase  : NAC activated method (kinetic) 
3. Magnesium  : Chlorphosphonazo III 
First, the clinical severity by POP scoring were correlated with 
initial serum creatine kinase and magnesium levels. 
Patients had been treated with our usual protocol with atropine and 
pralidoxime along with the usual care of poisoned patients.  Atropine 
chart, input output chart, pulse / blood pressure chart, RFT chart had been 
maintained.  Cardiac and SPO2 monitoring also done.  Mechanical 
ventilation was considered with indications.  The clinical course in terms 
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of atropine dose requirement, duration of hospital stay and development 
of complications like mechanical ventilation, intermediate syndrome, 
arrhythmias, renal failure, seizure, coma were correlated with the initial 
serum creatine kinase and magnesium levels. 
Statistical methods 
 Statistical analysis was done using SPSS software. The following 
statistical methods have been employed for analysis: 
1. Chi-square test 
2. Unpaired student t-test 
3. Analysis of variance (ANOVA) 
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RESULTS 
DESCRIPTION OF STUDY POPULATION 
Table : 1  AGE & SEX DISTRIBUTION  
Age group Male Female Total Percentage 
<20 3 8 11 18.3% 
21 – 30 10 12 22 36.7% 
31 – 40 8 8 16 26.7% 
>40 8 3 11 18.3% 
Total 29 31 60 100% 
 In our series, among 60 patients taken for study.  37% constitutes the 
age group between 21 – 30 years.  The number of people between the age 
group of 21 – 40 accounts for 38 out of 60 cases, which forms the majority.  
Female population predominates with 52%. 
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Table : 2 OCCUPATION  
 Male Female 
Frequency 
(n) 
Percentage 
AGRICULTURE 19 4 23 38% 
NON-AGRICULTURE 10 27 37 62% 
 
 
 Agriculturists make only 38% in our study population.  Male patients 
dominate in agriculture and female patients dominate in non-agriculture as 
occupation. 
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Table : 3 ROUTE OF EXPOSURE  
Route Male Female 
Frequency 
(n) 
INHALATION 1 0 1 
INGESTION 28 31 59 
TOTAL 29 31 60 
 
 Almost all the patients are exposed to organophosphorus compounds by 
ingestion (n=59) except only one who has been exposed through inhalation 
(n=1). 
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Table 4 : QUANTUM OF EXPOSURE AND OUTCOME 
QUANTITY 
CONSUMED (ml) 
OUTCOME 
DISCHARGE DEATH 
NA 01 0 
<50 ml 29 01 
51 – 100 ml 20 04 
>100 ml 03 02 
TOTAL 53 07 
 
 There is no clear correlation between the amount of exposure to 
compounds to the outcome including death (p=0.085).  There are also other 
factors important in predicting the outcome like route of exposure, type of 
compounds, quantum of absorption, hydrolytic capacity, excretion, etc.,  
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Table : 5 CLINICAL SEVERITY AND TIME OF ARRIVAL TO 
HOSPITAL 
TIME OF 
ARRIVAL 
CLINICAL SEVERITY 
P value 
MILD MODERATE SEVERE 
0 – 3 Hrs 01 02 06 
0.023 
4 – 6 Hrs 16 13 08 
7 – 9 Hrs 05 07 0 
10 – 12 Hrs 01 01 0 
TOTAL 23 23 14 
 The severity of poisoning makes the patient seeking the health care 
centre earlier and it seems to be significant (p = 0.023) 
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Table 6 : QUANTUM OF EXPOSURE AND  CLINICAL 
SEVERITY BY POP SCORING 
QUANTITY (ml) 
CLINICAL SEVERITY 
P value 
MILD MODERATE SEVERE 
<50 ml 18 09 03 
0.007 
51 – 100 ml 04 12 08 
>100 ml 0 02 04 
TOTAL 22 23 15 
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Table 7 : CLINICAL SEVERITY AND OUTCOME 
CLINICAL 
SEVERITY 
OUTCOME 
P value 
DISCHARGE DEATH 
MILD 23 0 
0.085 
MODERATE 20 3 
SEVERE 10 4 
TOTAL 53 7 
 Most of the deaths in the study population occurred from the category of 
moderate and severe poisoning classified accordingly by POP score (p=0.031).  
Thus the assessment of clinical severity by Peradeniya Organophosphorus 
Poisoning scale seems reliable.  Hence, it is used for the correlation of initial 
serum creatine kinase and magnesium levels with the complications and 
clinical outcome. 
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Table 8 : CLINICAL SEVERITY AND INITIAL MEAN SERUM 
CK VALUES 
CLINICAL SEVERITY 
Mean CK 
(IU/L) 
P value 
MILD 147 
<0.001 MODERATE 607.2 
SEVERE 3171.2 
 The clinical severity positively correlates with the initial mean serum 
creatine kinase levels (p <0.001).  Thus, the severe poisoning cases will have 
high serum creatine kinase levels at admission and mild poisoning have normal 
levels while moderate cases lie in between and is significant.  This elevation of 
serum creatine kinase is due to the muscle fiber necrosis produced due to the 
high toxicity of the OPC compounds.   
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Table 9 : CLINICAL SEVERITY AND INITIAL MEAN 
MAGNESIUM VALUES 
CLINICAL SEVERITY 
Mean Magnesium 
(mg/dl) 
P value 
MILD 1.9 
<0.001 MODERATE 1.64 
SEVERE 1.55 
 
 As severity of organophosphorus poisoning is associated with the 
reducing levels of serum magnesium, it has negative correlation (p <0.001) 
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Table 10 : TIME OF ARRIVAL AND MEAN CK VALUES 
TIME OF ARRIVAL (hrs) 
Mean CK 
values(IU/L) 
P value 
0 – 3  3010.6 
0.002 
4 – 6  748.3 
7 – 9 550.9 
10 – 12 175 
 
 The patients seeking hospital earlier i.e. within 3 hours of exposure had 
elevated serum Creatine kinase levels and it makes significant correlation                
(p = 0.002). 
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Table 11 : TIME OF ARRIVAL AND MEAN MAGNESIUM 
VALUES 
TIME OF ARRIVAL (hrs) 
Mean Mg 
values(mg/dl) 
P value 
0 – 3  1.58 
0.108 
4 – 6  1.74 
7 – 9 1.78 
10 – 12 1.80 
 
 Initial serum magnesium levels at admission has no correlation with 
time of arrival to the hospital (p = 0.108) 
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Table 12 : QUANTUM  OF EXPOSURE AND INITIAL MEAN CK 
VALUES 
AMOUNT OF POISON 
(ml) 
INITIAL MEAN CK 
LEVELS(IU/L) 
P value 
<50 ml 489.4 
0.049 51 – 100 ml 1591.8 
> 100 ml 920.4 
 
The quantum of exposure is directly proportional to the increased serum 
creatine kinase levels (p = 0.049) 
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Table 13 : QUANTUM OF EXPOSURE AND INITIAL MEAN 
MAGNESIUM VALUES 
AMOUNT OF POISON 
(ml) 
INITIAL MEAN 
MAGNESIUM 
LEVELS(mg/dl) 
P value 
<50 ml 1.83 
<0.001 51 – 100 ml 1.62 
> 100 ml 1.66 
 
The quantity of compounds exposed negatively correlate with the serum 
magnesium levels. (p <0.001) 
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Table 14 : CLINICAL SEVERITY AND DURATION OF 
HOSPITAL STAY 
CLINICAL 
SEVERITY 
DURATION OF HOSPITAL STAY 
(DAYS) 
P value 
<7 8 - 14 15 – 21 >21 
<0.001 
MILD 22 01 01 0 
MODERATE 05 11 05 2 
SEVERE 0 02 05 7 
 The duration of hospital stay positively correlates with the clinical 
severity at admission (p <0.001).  Hence, the patients admitted as severe 
poisoning clinically, will have prolonged hospital stay due to the development 
of complications like ventilator requirement, dialysis for renal failure, etc.,  
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Table 15 : DURATION OF HOSPITAL STAY AND INITIAL 
MEAN  
CK VALUES 
DURATION OF STAY 
(DAYS) 
INITIAL MEAN CK 
LEVELS(IU/L) 
P value 
<7 188.4 
<0.001 
8 – 14  774.2 
15 – 21 890.4 
>21 4088.6 
 In patients with raised serum creatine kinase levels, at admission, 
prolonged hospital stay can be expected due to development of various 
complications, as it has positive correlation (p <0.001) 
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Table 16 : DURATION OF HOSPITAL STAY AND INITIAL 
MEAN  
MAGNESIUM VALUES 
DURATION OF STAY 
(DAYS) 
INITIAL MEAN 
MAGNESIUM  
LEVELS(mg/dl) 
P value 
<7 1.85 
<0.001 
8 – 14  1.68 
15 – 21 1.63 
>21 1.52 
 
 Reduced serum magnesium levels at the time of admission leads to 
prolonged hospital stay as it has negative correlation (p <0.001) 
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Table 17 : FREQUENCY OF SUBSTANCE EXPOSED 
Sl.No. COMPOUNDS FREQUENCY 
1. DIAZINON 01 
2. QUINALPHOS 01 
3. CHLORPYRIFOS 16 
4. DICHLOROVAS 01 
5. DIMETHOATE 10 
6. MONOCHROTOPHOS 9 
7. PROPENOPHOS 08 
8. TEMIPHOS 06 
9. TRIAZOPHOS 08 
 Most of the patients in this series consumed Chlorpyrifos (n=16) and 
Dimethoate (n=10).  But, the type of poison does not contribute to severity or 
mortality.  
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Table 18 : FREQUENCY OF RENAL FAILURE WITH INITIAL 
   SERUM CK VALUES COMPARED TO CLINICAL  
SEVERITY 
CLINICAL 
SEVERITY  
RENAL 
FAILURE(n) 
MEAN 
INITIAL CK 
VALUES(IU/L) 
P value 
MILD (n = 23) 0 0 
0.002 MODERATE (n = 23) 9 526.3 
SEVERE (n = 14) 5 4249 
 
The incidence of renal failure positively correlates with the raised values 
of serum creatine kinase at admission (p = 0.002) 
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Table 19 : FREQUENCY OF RENAL FAILURE WITH INITIAL  
              SERUM Mg VALUES COMPARED TO CLINICAL  
SEVERITY 
CLINICAL 
SEVERITY  
RENAL 
FAILURE(n) 
MEAN INITIAL 
MgVALUES(mg/dl) 
P value 
MILD (n = 23) 0 0 
0.153 
MODERATE (n = 
23) 
9 1.67 
SEVERE (n = 14) 5 1.56 
 
 Though the incidence of renal failure is common in patients with initial 
reduced serum magnesium levels, it does not have significance (p = 0.153). 
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Table 20 : CLINICAL SEVERITY AND MEAN pH VALUES 
CLINICAL SEVERITY  MEAN pH P value 
MILD 7.36 
0.028 MODERATE 7.35 
SEVERE 7.35 
 
 Increasing severity of organophosphorus poisoning at admission 
negatively correlates with arterial pH values and its complications (p = 0.028)    
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Table 21 : ARRYTHMIAS AND INITIAL MEAN CK LEVELS 
 COMPARED TO CLINICAL SEVERITY  
CLINICAL 
SEVERITY  
ARRYTHMIAS 
(n) 
INITIAL 
SERUM MEAN 
CK LEVELS 
(IU/L) 
P value 
MILD (n = 23) 0 0 
0.624 MODERATE (n = 23) 1 1320.0 
SEVERE (n = 14) 2 2472.5 
Though the patients who developed arrhythmias had come under 
moderate and severe poisoning category, it carries no significant correlation.  
Also, the incidence of arrhythmias does not correlate with the initial serum 
creatine kinase levels (p = 0.624).  
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Table 22 : ARRYTHMIAS AND INITIAL MAGNESIUM LEVELS  
                      COMPARED TO CLINICAL SEVERITY  
CLINICAL 
SEVERITY  
ARRYTHMIAS 
(n) 
INITIAL MEAN 
SERUM 
MAGNESIUM  
LEVELS (mg/dl) 
P value 
MILD (n = 23) 0 0 
0.333 
MODERATE 
(n = 23) 
01 1.5 
SEVERE (n = 
14) 
02 1.6 
 
 The incidence of arrhythmias does not correlate with the initial serum 
magnesium levels (p = 0.333) 
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Table 23 : ATROPINE DOSE REQUIREMENT AND CLINICAL 
SEVERITY  
ATROPINE DOSE 
REQUIREMENT  
(No. of vials) 
CLINICAL SEVERITY 
MILD MODERATE SEVERE 
<10 14 01 0 
11 – 20  08 05 01 
21 – 30 01 12 04 
31 – 40  0 05 05 
41 – 50  0 0 03 
>50 0 0 01 
 Patients admitted as severe poisoning category will require large doses 
of atropine as revealed from the table above.  Hence, we conclude that the 
clinical severity as estimated from POP score is worth taking to correlate with 
the laboratory parameters and outcome in acute organophosphorus poisoning.  
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Table 24 : ATROPINE DOSE REQUIREMENT AND INITIAL 
MEAN CK LEVELS 
ATROPINE DOSE 
REQUIREMENT  
(No. of vials) 
INITIAL 
MEAN CK 
(IU/L) 
P value 
<10 142.8 
<0.001 
11 – 20  338.3 
21 – 30 881.1 
31 – 40  1727.5 
41 – 50  4804.0 
>50 8200.0 
 The comparison of atropine dose requirement and initial mean serum 
creatine kinase is significant with the positive correlation (p <0.001) 
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Table 25 : ATROPINE DOSE REQUIREMENT AND INITIAL 
MEAN MAGNESIUM LEVELS  
ATROPINE DOSE 
REQUIREMENT  
(No. of vials) 
INITIAL 
MEAN Mg 
(mg/dl) 
P value 
<10 1.90 
<0.001 
11 – 20  1.76 
21 – 30 1.66 
31 – 40  1.64 
41 – 50  1.43 
>50 1.33 
The comparison of atropine dose requirement and initial mean serum 
magnesium level is significant with the negative correlation (p <0.001)  i.e. 
patients with low serum magnesium level at admission will require large doses 
of atropine. 
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Table 26 : SEIZURES AND INITIAL SERUM CK LEVELS     
      COMPARED TO  CLINICAL SEVERITY  
CLINICAL SEVERITY  SEIZURE(n) 
INITIAL MEAN CK 
VALUE (IU/L) 
MILD (n = 23) 0 0 
MODERATE (n = 23) 1 810 
SEVERE (n = 14) 0 0 
 
Only one patient from moderate poisoning category developed seizures 
with mildly elevated serum creatine kinase level at admission and it cannot be 
considered as significant.   
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Table 27 : SEIZURES AND INITIAL SERUM MAGNESIUM  
                   LEVELS COMPARED TO CLINICAL SEVERITY  
CLINICAL SEVERITY  SEIZURE(n) 
INITIAL MEAN SERUM 
MAGNESIUM VALUE 
(mg/dl) 
MILD (n = 23) 0 0 
MODERATE (n = 23) 1 1.5 
SEVERE (n = 14) 0 0 
 
Patient who developed seizures, belonging to moderate poisoning 
category, had the initial serum magnesium value of 1.5 mg/dl and it cannot be 
considered for correlation. 
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Table 28 :  COINCIDENCE OF COMA AND INITIAL SERUM CK  
LEVELS TO CLINICAL SEVERITY 
CLINICAL SEVERITY  
COMA  
(n) 
INITIAL 
MEAN 
SERUM 
CK 
VALUES 
(IU/L) 
MILD (n = 23) 0 0 
MODERATE (n = 23) 0 0 
SEVERE (n = 14) 3 4790 
From the table, we conclude that three patients from severe poisoning 
category went into comatose state, with the elevated mean serum creatine 
kinase levels, but it could not be correlated.  
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Table 29 : COINCIDENCE OF COMA AND INITIAL MEAN  
                        MAGNESIUM LEVELS COMPARED TO 
CLINICAL  
SEVERITY 
CLINICAL SEVERITY  
COMA  
(n) 
INITIAL MEAN 
SERUM 
MAGNESIUM 
VALUE (mg/dl) 
MILD (n = 23) 0 0 
MODERATE (n = 23) 0 0 
SEVERE (n = 14) 3 1.48 
 
Among the severe poisoning category, three patients went into comatose 
state with low mean serum magnesium levels.   
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Table 30 : MECHANICAL VENTILATION REQUIREMENT AND  
                  INITIAL MEAN SERUM CK VALUES COMPARED TO  
CLINICAL SEVERITY 
CLINICAL 
SEVERITY  
MECHANICAL 
VENTILATION  
(n) 
INITIAL 
MEAN 
CK 
LEVELS 
(IU/L) 
P value 
MILD  
(n = 23) 
01 162 
0.005 
MODERATE  
(n = 23) 
14 716.9 
SEVERE  
(n = 14) 
13 3238.2 
 
The initial serum creatine kinase levels positively correlates with the 
requirement of mechanical ventilation in due course. (p = 0.005). 
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Table 31 :   MECHANICAL VENTILATION REQUIREMENT 
AND 
                   INITIAL MEAN MAGNESIUM VALUES COMPARED 
TO CLINICAL SEVERITY 
CLINICAL 
SEVERITY  
MECHANICAL 
VENTILATION  
(n) 
INITIAL 
MEAN 
MAGNESIUM 
LEVELS 
(mg/dl) 
P value 
MILD  
(n = 23) 
01 1.9 
0.008 
MODERATE  
(n = 23) 
14 1.66 
SEVERE  
(n = 14) 
13 1.59 
Those with the low initial serum magnesium levels will have more 
requirements of mechanical ventilation and its correlation is significant. (p = 
0.008). 
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Table 32 : INTERMEDIATE SYNDROME AND INITIAL MEAN  
             SERUM CK VALUES COMPARED TO CLINICAL  
SEVERITY 
CLINICAL 
SEVERITY  
INTERMEDIATE 
SYNDROME 
(n) 
INITIAL 
MEAN 
CK 
LEVELS 
(IU/L) 
P value 
MILD  
(n = 23) 
01 135 
0.005 
MODERATE  
(n = 23) 
05 704 
SEVERE  
(n = 14) 
04 2173 
The incidence of intermediate syndrome correlates with the 
categorization of clinical severity .  It also has meaningful significance 
comparing to the initial serum creatine kinase levels (p = 0.005). 
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Table 33 : INTERMEDIATE SYNDROME AND INITIAL MEAN  
                  MAGNESIUM VALUES COMPARED TO CLINICAL  
SEVERITY  
CLINICAL 
SEVERITY  
INTERMEDIATE 
SYNDROME 
(n) 
INITIAL 
MEAN 
MAGNESIUM 
LEVELS 
(mg/dl) 
P value 
MILD  
(n = 23) 
01 1.6 
0.141 
MODERATE  
(n = 23) 
05 1.67 
SEVERE  
(n = 14) 
04 1.50 
 
The incidence of intermediate syndrome among the study population 
does not correlate with the initial serum magnesium levels (p = 0.141). 
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Table 34 : INCIDENCE OF DEATH AND INITIAL MEAN SERUM  
              CK VALUES COMPARED TO CLINICAL SEVERITY  
CLINICAL 
SEVERITY  
DEATH 
(n) 
INITIAL 
MEAN 
CK 
LEVELS 
(IU/L) 
P value 
MILD  
(n = 23) 
0 0 
0.005 
MODERATE  
(n = 23) 
03 1200.66 
SEVERE  
(n = 14) 
04 3503.75 
 
Death rate increases in both moderate and severe poisoning and it also 
positively correlates with initial mean serum creatine kinase levels. (p = 0.005). 
  
70 
 
Table 35 : INCIDENCE OF DEATH AND INITIAL MAGNESIUM  
         VALUES COMPARED TO CLINICAL SEVERITY  
CLINICAL 
SEVERITY  
DEATH 
(No.of patients) 
INITIAL 
MEAN 
MAGNESIUM 
LEVELS 
(mg/dl) 
P value 
MILD  
(n = 23) 
0 0 
0.024 
MODERATE  
(n = 23) 
03 1.62 
SEVERE  
(n = 14) 
04 1.56 
 
The incidence of death is more in moderate and severe poisoning who 
had the initial low serum magnesium levels and it carries significance.  (p = 
0.024).  
 
  
0 0.5 1 1.5 2
Mild (n=0)
Moderate (n=3)
Severe (n=4)
mg/dL
Mean magnesium
Mean magnesium
71 
 
Table 36 :CLINICAL SEVERITY COMPARED TO INITIAL 
MEAN SERUM CK AND AchE LEVELS  
CLINICAL 
SEVERITY  
INITIAL 
MEAN 
CK 
LEVELS 
(IU/L)) 
P value 
INITIAL 
MEAN AchE 
LEVELS 
(IU/L) 
P value 
MILD  
(n = 23) 
0 
<0.001 
0 
0.002 
MODERATE  
(n = 23) 
1200.66 1.62 
SEVERE  
(n = 14) 
3503.75 1.56 
 
Clinical severity has positive correlation with the initial serum creatine 
kinase (p <0.001) and negative correlation with initial serum 
acetylcholinesterase levels (p = 0.002). 
 
  
72 
 
DISCUSSION 
Epidemiology of Organophosphorus poisoining 
 In this series, the organophosphorus poisoning was most prevalent in the 
age group 21 – 30 years.  49 cases out of 60 were below the age of 40 years.  
Pyar Ali et al observed the mean age group of 28.6 +9.8 years from Karachi.  
Another study from Karachi by Aftab Turab et al observed the age group of 15 
– 20 years (44.77%) as predominant.  Murat Sungur et al from Turkey 
observed the mean age group as 30 +15 years.  Karalliedde L., Senanayake N. 
et al of Srilanka documented 91% of their cases were under the age of 30.  
Malik et al from Kashmir, revealed the predominant population affected by 
OPC exposure were under the age of 25.  In Mangalore, Karnataka, India, the 
most common age group to be affected was between 20 – 30 (36.6%).  Kuntal 
Battacharyya et al of Kolkata reported the mean age of 25.5 years.  This young 
age group affected by exposure and also in terms of procurement and 
productivity.  This study throw light on the target age group by improving the 
management protocol and decreasing the mortality.   
 In our series, females (n=31) dominated the study population.  Probably 
many male patients were excluded from study due to the mixed poison with 
alcohol.  Malik et al observation of 122 cases in Kashmir valley (females 
n=114, males n=50), female intoxication was more.  In Mangalore and Srilanka 
had pattern to the case series with male predominance.  S.Shivakumar and 
K.Raghavan et al of Tamilnadu reported 165 cases of organophosphorus 
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poisoning and sex distribution was with male predominance.  Kuntal 
Battacharya et al from Kolkata showed male predominance.  In Southern part 
of India, males are actively involved in spraying fertilizers and pesticides.   
  In our case series, 23 out of 60 (38.3%) were agriculturists.   Non 
agriculturist were exposed more to organophosphorus compounds with the 
suicidal intent.  Agriculturist, also accidentally exposed due to the spraying in 
the field.  In Kashmir Valley, two third of the population who had exposed 
were engaged in apple orchard.   
 In our series, most of the cases occurred due to ingestion (98.3%) and 
only one had accidental inhalation (1.7%).  The common organophosphorus 
compounds abused in our series are chlorpyrifos and dimethoate.  Kuntal 
Bhattacharyya et al also described the most frequent compound as Chlorpyrifos 
(38.1%). 
Clinical severity by Peradeniya Organophosphorus Poisoning scale 
 Kuntal Bhattacharyya et al of Kolkata correlated initial serum creatine 
kinase with the clinical severity by POP scoring and outcome.  In our study, 
POP scoring was much reliable that it correlated clearly with the duration of 
hospital stay, development of complications, quantum of exposure and initial 
serum creatine kinase, magnesium values.   
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Laboratory correlates: 
Serum Creatine Kinase 
 Patients with acure organophosphorus poisoning are usually monitored 
by using serum acetylcholinesterase levels which are expected to fall.  But, this 
investigation can not be available in every hospital and is also expensive.  
Hence, we preferred the estimation of serum creatine kinase instead, which is 
cheaper. 
 The initial rise of serum creatine kinase in severe acute 
organophosphorus poisoning is probably due to the presence of muscle fiber 
necrosis.  This has been demonstrated in two patients by Kuntal Bhattacharyya 
et al. This occurred even before the development of intermediate syndrome in 
which CK level is expected to rise.  The mean half life of CK is about 1.5 days.  
With the good management, CK levels may be reduced to normal within 5 days 
if patient does not develop intermediate syndrome. 
 In our study, raised serum CK levels at admission significantly 
correlated with the initial clinical severity by POP scoring, increased atropine 
requirement, duration of hospital stay.  It also correlated with the incidence of 
intermediate syndrome, arrythmias, renal failure, coma, outcome.  Thus, with 
the morbidity and mortality, it had the pattern of negative correlation with the 
serum cholinesterase levels at admission.  Hence, we concluded that initial 
serum creatine kinase can be used as parameter for assessing the severity and 
outcome of acute organophosphorus poisoning replacing serum 
acetylcholinesterase levels.    
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Serum Magnesium 
 Hypomagnesemia seems to occur in any critical illness patients 
according to various studies.  Hypomagnesemia in acute organophosphorus 
poisoning cases might be due to GI losses, vomiting, diarrhoea, prolonged 
gastric aspiration, etc.,  Magnesium is one of the omitted electrolyte in any 
illness.   Since, many manifestations of hypomagnesemia overlap with features 
of organophosphorus poisoning, it may be the contributory factor in severity 
and outcome.   
 In our study, decreased serum magnesium levels at admission correlated 
with poor outcome in the form of increased atropine requirement, duration of 
hospital stay, incidence of intermediate syndrome, mechanical ventilation, 
death and not correlated with the incidence of renal failure, seizures and 
arrythmias.   
 There are studies regarding the beneficial effects of intravenous 
magnesium sulfate in the management protocol of organophosphorus 
poisoning.  The mechanism for magensium sulfate is blocking of ligand gated 
calcium channels, resulting in reduced acetylcholine release from pre-synaptic 
terminals. 
 Hence, it is our opinion from the study that initial reduced serum 
magnesium level will correlate with poor clinical outcome and intravenous 
magnesium sulfate also corrects hypomagnesemia in addition to the reduction 
in acetylcholine relase from pre synaptic terminals, thus reducing morbidity 
and mortality.    
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CONCLUSION 
 
1. Peradeniya Organophosphorus Poisoning scale is the excellent 
classification system for categorising the severity of cases with acute 
organophosphorus poisoning. 
2. Serum creatine kinase can be an efficient biomarker as predictor of 
severity of acute organophosphorus poisoning and be used instead of 
serum acetylcholinesterase levels considering the cost and non-
availability. 
3. Serum magnesium can be used as the predictor of severity of acute 
organophosphorus poisoning and intravenous magnesium sulfate to 
be considered for correction to reduce the morbidity and mortality.   
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RECOMMENDATIONS AND AREAS OF FUTURE 
RESEARCH 
1. Research into the cause for hypomagnesemia in organophosphorus 
poisoning is worth to be considered. 
2. The role of intravenous magnesium sulfate in organophosphorus 
poisoning needs to be studied in our Indian context and to be 
included in management protocol.   
3. The role of oximes is challenged by many studies.  Hence, a large 
high quality RCT comparing the current WHO recommended 
regimen with placebo is required to assess the value of pralidoxime 
in acute organophosphorus poisoning. 
4. The role of newer management like fresh frozen plasma therapy, 
organophosphorus hydrolases, Butrylcholinesterase replacement 
therapy, α2 adrenergic receptor agonist, extra corporeal clearance 
needs to be studied to improve the survival rates.   
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SUMMARY 
 Organophosphorus poisoning is a menace to the human race both as a 
weapon of mass destruction and a misused pesticide of self-harm.  The case  
fatality rate exceeded 60% in developing countries where there are many 
pitfalls in treatment protocol and research activities.  Hence, we conducted a 
study with 60 patients for the possible role of serum creatine kinase and 
magnesium at poison centre, Rajiv Gandhi Government General Hospital, 
Chennai.   
 We found that, raised serum creatine kinase and reduced serum 
magnesium levels in acute organophosphorus poisoning at admission indicates 
poor outcome and emphasized the future research regarding the beneficial 
effect of intermediate magnesium sulfate for correcting hypomagnesemia to 
reduce the morbidity and mortality.  
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SERUM CREATINE PHOSPHOKINASE AND MAGNESIUM 
AS PROGNOSTIC INDICATORS IN ACUTE 
ORGANOPHOSPHORUS POISONING 
Name : 
Age/Sex : 
IP No : 
Patient ID No : 
Symptoms 
❏ Vomiting ❏ Palpitations 
❏ Loose stools ❏ Blurring of vision 
❏ Salivation/Lacrimation/Sweating ❏ Seizures 
❏ Dyspnea ❏ Loss of consciousness 
Poisoning Past history 
Compound  ❏ DM 
Amount  ❏ HT 
Time of consumption  ❏ CAD 
❏ Empty stomach ❏ Bronchial Asthma/COPD 
Personal history 
❏ Smoking ❏ Alcoholism 
 
Peradeniya Organophosphorus Poisoning scale 
Parameters 0 1 2 Score 
Pupil size ≥2 mm <2 mm Pinpoint  
Respiratory rate <20/min ≥20/min 
≥20/min with 
central 
cyanosis 
 
Heart rate >60/min 41-60/min <40/min  
Fasciculation None 
Present 
Generalized / 
continuous 
Both 
generalized 
and 
continuous 
 
Level of 
consciousness 
Conscious and 
rationale 
Impaired 
response to 
verbal 
commands 
No response to 
verbal 
commands 
 
Seizures Absent Present -  
Grade Mild [0-3] Moderate [4-7] Severe [8-11]  
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Systemic examination 
CVS  
RS  
Abdomen  
CNS  
 
INVESTIGATIONS 
RFT LFT 
Glucose 
(Fasting) 
 mg/dl Total bilirubin  mg/dl 
Urea  mmol/l Direct bilirubin  mg/dl 
Creatinine  mmol/l SGOT  U/l 
Electrolytes SGPT  U/l 
Na
+
  mEq/l ALP  U/l 
K
+
  mEq/l Total protein  g/dl 
Mg
2+
  mEq/l Albumin  g/dl 
CPK  IU/l AchE  IU/l 
ECG  
Chest X-ray  
 
Course 
 D1 D2 D3 D4 D5 D6 D7 D14 D21 
Atropine 
requirement 
         
Mechanical 
ventilation 
         
Arrhythmias          
Renal failure          
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ஆராசிதகவதா 
ெசைனஇராஜிகாதிஅரெபாமவமைனயிஅமதிகப
சிெகா மதிைனஉ"ெகா#டேநாயாளிகைளப(றியஒஆரா,
சிநைடெப(-வகிற. 
சிெகா மதிைனஉ"ெகா#டேநாயாளிகளிநபாதிபி
தீவிரைதஇரததிஏ(பசிலேவதியியமா(ற1களி2லஅறிவேதஇ
தஆரா,சியிேநாகமா3. 
நீ1க4இதஆரா,சியிப1ேக(கநா1க5வி6கிேறா. 
789கைளஅலககைளெவளியிேபாேதாஅலஆரா,சியி
ேபாேதாத1களெபயைரேயாஅலஅைடயாள1கைளேயாெவளியிடமா"
ேடாஎபைத;ெதாிவிெகா5கிேறா. 
இதஆரா,சியிப1ேக(பத1க4ைடயவிபதிேபாிதாஇ
கிற. 
ேம<நீ1க5எேநர7இதஆரா,சியி பிவா1கலாஎபைத;
ெதாிவிெகா5கிேறா. 
இதசிற6பாிேசாதைனகளி789கைளஆரா,சியிேபாஅல
ஆரா,சியி78வித1க43அறிவிேபாஎபைத;ெதாிவி
ெகா5கிேறா. 
 
ஆரா,சியாள= ைகெயாப ப1ேக(பாள= ைகெயாப 
 
 
ேததி: 
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ஆராஒ	தகத 
ஆரா,சி தைல6: 
சி ெகா  மதிைன உ"ெகா#ட ேநாயாளிகளி ந 
பாதிபி தீவிரைத இரததி ஏ(ப சில ேவதியிய மா(ற1களி 
2ல அறிவ ப(றிய ஆரா,சி. 
 
ெபய=: ேததி: 
வய: உ5ேநாயாளி எ#: 
பா: ஆரா,சி ேச=ைக எ#: 
 
இத ஆரா,சியி விவர1க4 அத ேநாக1க4 7Aைமயாக 
என3 ெதளிவாக விளகப"ட. என3 விளகப"ட விஷய1கைள 
நா 6ாி ெகா# நா என சமதைத ெதாிவிகிேற. 
சி ெகா  ம உ"ெகா5வதா ஏ(ப பாதி6க5 
3றி, அத தீவிரைத க#டறிய ேம(ெகா5ளப பாிேசாதைனக5 
3றி ஆரா,சியாள= Cற 7Aவ விள1கெப(ேற. 
ேம(ெகா#ட பாிேசாதைனயி ேபா ஏ(படC8ய 
பிவிைள9கைள; 7Aவ உண= இத பாிேசாதைன3 மனமார 
சமதிகிேற. 
 
ைகெயாப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1 42 M Agri Triazophos ING 20 10 MILD NORMAL NORMAL 137 3.5 7.37 9.8 
2 21 F Non-Agri chlorpyrifos ING 50 4 MILD NORMAL NORMAL 142 3.9 7.34 9.8 
3 23 F Non-Agri chlorpyrifos ING 80 5 SEVERE NORMAL NORMAL 142 3.1 7.3 8.6 
4 45 M Agri Temephos ING 45 8 MILD NORMAL NORMAL 151 4.2 7.38 8.9 
5 21 F Non-Agri Monochrotophos ING 30 4 MODERATE NORMAL NORMAL 134 3.9 7.36 8.8 
6 35 F Non-Agri Triazophos ING 45 4 MILD NORMAL NORMAL 143 4.2 7.35 10.2 
7 18 F Non-Agri Dimethoate ING 70 3 MODERATE NORMAL NORMAL 133 3.2 7.34 9.4 
8 24 F Non-Agri Monochrotophos ING 120 6 MODERATE NORMAL NORMAL 137 4.3 7.42 10.1 
9 55 M Agri Prophenophos ING 100 6 MODERATE NORMAL NORMAL 145 3.5 7.44 8.6 
10 34 F Agri Triazophos ING 150 5 SEVERE NORMAL ABN 136 3.9 7.36 9.3 
11 28 M Agri Triazophos ING 60 5 MILD NORMAL NORMAL 136 4.3 7.43 8.9 
12 25 M Non-Agri Monochrotophos ING 20 7 MODERATE NORMAL ABN 142 4.1 7.42 8.7 
13 55 M Agri Dichlorovas ING 100 11 MODERATE NORMAL ABN 130 4.3 7.2 8.6 
14 19 M Non-Agri chlorpyrifos ING 60 6 SEVERE NORMAL NORMAL 143 4.1 7.42 9.8 
15 32 M Non-Agri Diazinon ING 70 4 SEVERE NORMAL NORMAL 136 4 7.33 9 
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16 34 F Agri Prophenophos ING 70 6 MILD NORMAL NORMAL 143 4.3 7.45 9.3 
17 26 F Non-Agri Prophenophos ING 15 8 MILD NORMAL NORMAL 144 4.7 7.4 8.9 
18 27 M Agri chlorpyrifos ING 30 7 MODERATE NORMAL ABN 126 4.8 7.41 8.9 
19 18 F Non-Agri Temephos ING 60 4 MODERATE NORMAL ABN 132 5.2 7.32 8.6 
20 16 M Non-Agri chlorpyrifos ING 100 5 SEVERE NORMAL NORMAL 136 4.2 7.43 8.7 
21 51 M Agri Dimethoate ING 100 6 MILD NORMAL NORMAL 142 4.4 7.36 8.6 
22 24 M Non-Agri Dimethoate ING 40 9 MILD NORMAL NORMAL 136 3.9 7.38 8.6 
23 51 M Agri Temephos ING 40 3 SEVERE NORMAL ABN 135 4.6 7.32 7.3 
24 18 F Non-Agri Prophenophos ING 20 4 MILD NORMAL NORMAL 143 3.8 7.39 8.9 
25 26 M Agri Dimethoate ING 150 7 MODERATE NORMAL NORMAL 135 3.7 7.32 9.8 
26 21 M Agri Prophenophos ING 70 3 SEVERE NORMAL ABN 135 3.8 7.43 8.9 
27 32 F Non-Agri Monochrotophos ING 60 5 SEVERE NORMAL NORMAL 130 3.1 7.3 9.2 
28 34 F Non-Agri Temephos ING 50 4 MILD NORMAL NORMAL 145 3.6 7.36 8.9 
29 25 F Non-Agri chlorpyrifos ING 30 4 MODERATE NORMAL NORMAL 138 3.8 7.4 8.7 
30 38 F Non-Agri Dimethoate ING 50 8 MILD NORMAL NORMAL 152 4.2 7.35 9.5 
31 31 M Agri Temephos ING 40 5 MILD NORMAL NORMAL 142 3.8 7.36 9.7 
32 29 M Agri Monochrotophos ING 60 9 MODERATE NORMAL ABN 134 4.2 7.33 9.8 
33 37 F Agri Triazophos ING 50 5 SEVERE NORMAL NORMAL 138 3.4 7.34 8.6 
34 28 M Non-Agri Chlorpyrifos ING 50 8 MODERATE NORMAL NORMAL 134 4.2 7.42 8.9 
35 24 M Agri chlorpyrifos ING 20 3 MODERATE NORMAL ABN 143 3.6 7.35 9.4 
36 26 F Non-Agri Monochrotophos ING 50 3 SEVERE NORMAL NORMAL 123 5.1 7.23 8.9 
37 41 F Agri Quinalphos ING 100 6 MODERATE NORMAL NORMAL 145 3.9 7.4 9.6 
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38 17 M Non-Agri Prophenophos ING 30 3 MILD NORMAL NORMAL 143 3.8 7.43 8.7 
39 18 F Non-Agri chlorpyrifos ING 40 6 MILD NORMAL NORMAL 144 4.3 7.4 8.7 
40 42 M Agri Dimethoate INH  6 MILD NORMAL NORMAL 145 4.5 7.45 9.2 
41 36 M Agri Monochrotophos ING 60 8 MODERATE NORMAL ABN 143 3.8 7.38 10.4 
42 34 M Non-Agri chlorpyrifos ING 50 6 MILD NORMAL NORMAL 136 3.6 7.43 10.2 
43 34 M Agri Prophenophos ING 100 4 MODERATE NORMAL NORMAL 143 3.8 7.42 8.9 
44 33 M Agri Prophenophos ING 50 6 MODERATE NORMAL ABN 145 4.1 7.36 8.8 
45 19 F Non-Agri Dimethoate ING 20 5 MILD NORMAL NORMAL 142 4.4 7.42 9.8 
46 24 F Non-Agri Monochrotophos ING 60 3 SEVERE NORMAL NORMAL 139 3.2 7.4 9.2 
47 31 M Non-Agri chlorpyrifos ING 100 5 MODERATE NORMAL NORMAL 135 4.5 7.36 8.8 
48 23 F Non-Agri chlorpyrifos ING 120 5 SEVERE NORMAL NORMAL 125 4.9 7.31 8.7 
49 27 F Non-Agri Triazophos ING 30 4 MILD NORMAL NORMAL 142 4.5 7.4 9.5 
50 45 M Non-Agri Chlorpyrifos ING 100 4 MILD NORMAL NORMAL 137 4.4 7.41 10.8 
51 35 F Non-Agri Dimethoate ING 70 8 MODERATE NORMAL NORMAL 129 3.8 7.36 9.6 
52 19 F Non-Agri Triazophos ING 30 5 MILD NORMAL NORMAL 136 4.2 7.43 9.6 
53 15 F Non-Agri Temephos ING 50 5 MODERATE NORMAL NORMAL 145 3.8 7.4 9.8 
54 26 F Non-Agri chlorpyrifos ING 40 5 MILD NORMAL NORMAL 151 4.2 7.43 9.8 
55 28 M Agri Dimethoate ING 35 7 MILD NORMAL NORMAL 143 4.4 7.32 9.2 
56 33 M Agri Triazophos ING 100 6 MODERATE NORMAL NORMAL 146 2 7.43 8.3 
57 24 F Non-Agri chlorpyrifos ING 150 3 SEVERE NORMAL ABN 134 3.4 7.2 6.8 
58 43 F Non-Agri Dimethoate ING 50 5 MODERATE NORMAL NORMAL 139 3.5 7.36 8.8 
59 43 F Non-Agri Monochrotophos ING 60 3 SEVERE NORMAL ABN 137 3.8 7.43 9.5 
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60 17 F Non-Agri chlorpyrifos ING 60 5 MODERATE NORMAL NORMAL 152 3.4 7.3 9.2 
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1 42 M 1.9 3300 140 A A 6 N  N N 4 Discharge 
2 21 F 2.1 2800 110 A A 6 N  N N 5 Discharge 
3 23 F 1.33 1320 8200 A A 52 Y 20 N Y 32 Death 
4 45 M 1.9 1467 145 A A 10 N  N N 6 Discharge 
5 21 F 1.7 1790 230 A A 32 N  N N 11 Discharge 
6 35 F 1.7 1300 70 A A 11 N  N N 7 Discharge 
7 18 F 1.5 2390 560 A A 23 Y 7 N N 20 Death 
8 24 F 1.6 1370 130 A A 21 Y 8 N N 16 Discharge 
9 55 M 1.7 2300 1700 A P 23 Y 6 N N 15 Death 
10 34 F 1.6 790 1480 P A 13 Y 6 N N 18 Death 
11 28 M 1.8 3200 135 A A 4 N  N N 6 Discharge 
12 25 M 1.7 2130 560 A P 24 N  N N 12 Discharge 
13 55 M 1.7 2120 210 A A 10 N  N N 7 Discharge 
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14 19 M 1.6 1320 2300 A A 23 N  N N 12 Discharge 
15 32 M 1.4 1423 512 A P 42 Y 8 N N 15 Discharge 
16 34 F 1.9 3300 165 A A 9 N  N N 6 Discharge 
17 26 F 2.1 3290 130 A A 12 N  N N 7 Discharge 
18 27 M 1.6 2430 780 A A 23 Y 4 N N 17 Discharge 
19 18 F 1.6 1690 580 A A 24 Y 4 N N 12 Discharge 
20 16 M 1.7 1200 870 A A 21 Y 8 N Y 31 Death 
21 51 M 1.6 2100 135 A P 9 N  N N 4 Discharge 
22 24 M 1.86 2434 211 A A 12 N  N N 7 Discharge 
23 51 M 1.5 980 5400 A A 34 Y 16 N N 23 Discharge 
24 18 F 2.2 2800 110 A A 4 N  N N 4 Discharge 
25 26 M 1.5 1980 1320 P A 32 Y 10 N N 23 Discharge 
26 21 M 1.6 1320 2300 A A 32 Y 7 N N 18 Discharge 
27 32 F 1.5 980 2300 A P 35 Y 7 N N 22 Discharge 
28 34 F 2.3 2670 152 A A 12 N  N N 7 Discharge 
29 25 F 1.5 2300 320 A A 12 N  N N 6 Discharge 
30 38 F 1.9 2700 160 A A 6 N  N N 5 Discharge 
31 31 M 1.9 1900 215 A A 12 N  N N 6 Discharge 
32 29 M 1.6 2100 890 A A 24 Y 7 N N 14 Discharge 
33 37 F 1.7 870 580 A P 31 Y 6 N N 15 Discharge 
34 28 M 1.8 4012 910 A A 21 N  N N 6 Discharge 
35 24 M 1.6 1420 460 A A 21 N  N N 12 Discharge 
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36 26 F 1.7 1230 790 A A 21 Y 8 N N 20 Discharge 
37 41 F 1.66 2013 280 A P 23 N  N N 6 Discharge 
38 17 M 1.8 1900 220 A A 12 N  N N 6 Discharge 
39 18 F 1.9 3190 127 A A 8 N  N N 5 Discharge 
40 42 M 1.9 3100 165 A A 3 N  N N 4 Discharge 
41 36 M 1.8 2130 560 A A 31 Y 5 N N 9 Discharge 
42 34 M 1.72 1300 126 A A 12 N  N N 5 Discharge 
43 34 M 1.7 1245 365 A A 21 Y 5 N N 12 Discharge 
44 33 M 1.8 1560 170 A P 18 Y 5 N N 13 Discharge 
45 19 F 1.72 2398 164 A A 12 N  N N 5 Discharge 
46 24 F 1.4 1100 5300 A P 45 Y 13 N Y 27 Discharge 
47 31 M 1.9 1230 320 A A 31 Y 4 N N 13 Discharge 
48 23 F 1.6 560 2300 A A 23 Y 6 N N 13 Discharge 
49 27 F 1.8 3010 90 A A 8 N  N N 5 Discharge 
50 45 M 1.9 1278 162 A A 21 Y 7 N N 16 Discharge 
51 35 F 1.6 2530 800 A A 34 Y 6 N N 16 Discharge 
52 19 F 2.1 3300 140 A A 5 N  N N 4 Discharge 
53 15 F 1.66 2149 1342 A A 24 Y 8 N N 23 Death 
54 26 F 1.9 3100 165 A A 5 N  N N 5 Discharge 
55 28 M 2 2870 145 A A 9 N  N N 6 Discharge 
56 33 M 1.41 1410 148 A A 19 N  N N 5 Discharge 
57 24 F 1.6 790 3465 P A 32 Y 13 N N 23 Death 
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58 43 F 1.7 2200 520 A A 18 Y 4 N N 13 Discharge 
59 43 F 1.5 1200 8600 A A 42 Y 12 N N 23 Discharge 
60 17 F 1.5 1560 810 A P 20 N  Y N 12 Discharge 
 
